Findings

What do systematic reviews say?

27 questions · 28 findings · 4 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 17.9%GRADE not reported 6 · 21.4%Very low 4 · 14.3%Low 6 · 21.4%Moderate 0 · 0%High 7 · 25%

BM‐MSC vs no treatment

Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low

BM‐MSC vs no treatment

Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 1.07 [0.94, 1.22]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.86 [0.62, 1.19]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.47 [0.13, 1.72]
1 study · 64 participants
Low

Intervention not reported

Adverse event: nausea · patients with ALS/MND

The intervention leads to higher adverse event: nausea (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.55 [1.06, 2.28]
3 studies · 801 participants
High

Intervention not reported

Adverse event: asthenia · patients with ALS/MND

The intervention leads to higher adverse event: asthenia (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 1.5 [1.07, 2.12]
3 studies · 801 participants
High

Intervention not reported

Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND

The intervention leads to higher adverse event: 3‐fold increase in alanine transferase (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 2.62 [1.59, 4.31]
3 studies · 801 participants
High